PETNET Signs Supply Deal with Lantheus for Cardiac Perfusion Trials

 

June 11, 2009

June 11, 2009 – PETNET Solutions, a subsidiary of Siemens Medical Solutions USA Inc. that manufactures and distributes radiopharmaceuticals, has signed a supply agreement with Lantheus Medical Imaging Inc. to provide BMS747158 for PET imaging of cardiac perfusion as part of the phase II and phase III trials.

PETNET Solutions/Siemens has previously supplied all of the clinical trial doses for the Lantheus Phase I study. BMS747158 is Lantheus’ novel fluorine 18-labeled positron emission tomography (PET) tracer for myocardial perfusion imaging in subjects under rest and stress conditions.

 

PETNET Solutions is committed to advancing molecular imaging by support of clinical trials.

 

“Our agreement with Lantheus further emphasizes PETNET’s network as an attractive channel for novel PET agents,” said Tom Welch, chief executive officer of PETNET Solutions. “We are proud to be involved with BMS747158 as one of the many important R&D projects that Siemens is actively engaged in.”

 

PETNET Solutions operates the largest PET radiopharmacy network with 52 radiopharmacies and distribution centers worldwide that manufacture and distribute PET biomarkers to hospitals, clinics, and research facilities for PET imaging. 

For more information: www.siemens.com/healthcare.